Chemopreventive Drugs: Mechanisms Via Inhibition of Cancer Stem Cells in Colorectal Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Apr 19

PMID 24744576

Citations 8

Authors

Tae Il Kim

Affiliations

Soon will be listed here.

Abstract

Recent epidemiological studies, basic research and clinical trials on colorectal cancer (CRC) prevention have helped identify candidates for effective chemopreventive drugs. However, because of the conflicting results of clinical trials or side effects, the effective use of chemopreventive drugs has not been generalized, except for patients with a high-risk for developing hereditary CRC. Advances in genetic and molecular technologies have highlighted the greater complexity of carcinogenesis, especially the heterogeneity of tumors. We need to target cells and processes that are critical to carcinogenesis for chemoprevention and treatment of advanced cancer. Recent research has shown that intestinal stem cells may serve an important role in tumor initiation and formation of cancer stem cells. Moreover, studies have shown that the tumor microenvironment may play additional roles in dedifferentiation, to enable tumor cells to take on stem cell features and promote the formation of tumorigenic stem cells. Therefore, early tumorigenic changes of stem cells and signals for dedifferentiation may be good targets for chemoprevention. In this review, I focus on cancer stem cells in colorectal carcinogenesis and the effect of major chemopreventive drugs on stem cell-related pathways.

Citing Articles

Bufalin Inhibits Tumorigenesis, Stemness, and Epithelial-Mesenchymal Transition in Colorectal Cancer through a C-Kit/Slug Signaling Axis.

Ding L, Yang Y, Lu Q, Qu D, Chandrakesan P, Feng H Int J Mol Sci. 2022; 23(21).

PMID: 36362141 PMC: 9656328. DOI: 10.3390/ijms232113354.

Metformin Suppresses Cancer Stem Cells through AMPK Activation and Inhibition of Protein Prenylation of the Mevalonate Pathway in Colorectal Cancer.

Seo Y, Kim J, Park S, Park J, Cheon J, Kim W Cancers (Basel). 2020; 12(9).

PMID: 32911743 PMC: 7563617. DOI: 10.3390/cancers12092554.

Inhibitory Effects of Peptide Lunasin in Colorectal Cancer HCT-116 Cells and Their Tumorsphere-Derived Subpopulation.

Fernandez-Tome S, Xu F, Han Y, Hernandez-Ledesma B, Xiao H Int J Mol Sci. 2020; 21(2).

PMID: 31947688 PMC: 7014180. DOI: 10.3390/ijms21020537.

Polyphenols: Immunomodulatory and Therapeutic Implication in Colorectal Cancer.

Mileo A, Nistico P, Miccadei S Front Immunol. 2019; 10:729.

PMID: 31031748 PMC: 6470258. DOI: 10.3389/fimmu.2019.00729.

Assessment of a mouse xenograft model of primary colorectal cancer with special reference to perfluorooctane sulfonate.

Wimsatt J, Montgomery C, Thomas L, Savard C, Tallman R, Innes K PeerJ. 2018; 6:e5602.

PMID: 30405966 PMC: 6216948. DOI: 10.7717/peerj.5602.

References

Jacoby R, Seibert K, Cole C, Kelloff G, Lubet R . The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 2000; 60(18):5040-4. View

Hawley S, Fullerton M, Ross F, Schertzer J, Chevtzoff C, Walker K . The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012; 336(6083):918-22. PMC: 3399766. DOI: 10.1126/science.1215327. View

Ziskin J, Dunlap D, Yaylaoglu M, Fodor I, Forrest W, Patel R . In situ validation of an intestinal stem cell signature in colorectal cancer. Gut. 2012; 62(7):1012-23. DOI: 10.1136/gutjnl-2011-301195. View

Xia D, Wang D, Kim S, Katoh H, DuBois R . Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med. 2012; 18(2):224-6. PMC: 3274627. DOI: 10.1038/nm.2608. View

Harada K, Higaki S, Amano A, Hashimoto K, Hashimoto S, Gondo T . A reduced COX-2 expression and a reduced number of pericryptal myofibroblasts are associated with depressed adenoma of the colon. Oncol Rep. 2007; 17(6):1353-8. View

Montgomery R, Carlone D, Richmond C, Farilla L, Kranendonk M, Henderson D . Mouse telomerase reverse transcriptase (mTert) expression marks slowly cycling intestinal stem cells. Proc Natl Acad Sci U S A. 2010; 108(1):179-84. PMC: 3017192. DOI: 10.1073/pnas.1013004108. View

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P . The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-86. DOI: 10.1038/sj.onc.1211024. View

Hsieh M, Lee T, Cheng S, Tu S, Yen M, Tseng C . The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012; 2012:413782. PMC: 3374948. DOI: 10.1155/2012/413782. View

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

10.

Adegboyega P, Mifflin R, DiMari J, Saada J, Powell D . Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps, and adenomatous colorectal polyps. Arch Pathol Lab Med. 2002; 126(7):829-36. DOI: 10.5858/2002-126-0829-ISOMIN. View

11.

Ma L, Niknejad N, Gorn-Hondermann I, Dayekh K, Dimitroulakos J . Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells. PLoS One. 2012; 7(9):e46055. PMC: 3460930. DOI: 10.1371/journal.pone.0046055. View

12.

Levy D, Moser A, Dove W, Hamilton S, Vogelstein B, Kinzler K . Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis. 1996; 17(8):1757-60. DOI: 10.1093/carcin/17.8.1757. View

13.

Colmers I, Bowker S, Johnson J . Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2012; 38(6):475-84. DOI: 10.1016/j.diabet.2012.06.003. View

14.

Sarraf P, Mueller E, Jones D, KING F, DeAngelo D, Partridge J . Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998; 4(9):1046-52. DOI: 10.1038/2030. View

15.

Medema J, Vermeulen L . Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature. 2011; 474(7351):318-26. DOI: 10.1038/nature10212. View

16.

Vinogradova Y, Coupland C, Hippisley-Cox J . Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer. 2011; 11:409. PMC: 3197575. DOI: 10.1186/1471-2407-11-409. View

17.

Eberhart C, Coffey R, Radhika A, Giardiello F, Ferrenbach S, DuBois R . Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107(4):1183-8. DOI: 10.1016/0016-5085(94)90246-1. View

18.

Shadman M, Newcomb P, Hampton J, Wernli K, Trentham-Dietz A . Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. World J Gastroenterol. 2009; 15(19):2336-9. PMC: 2684598. DOI: 10.3748/wjg.15.2336. View

19.

Sica A, Bronte V . Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007; 117(5):1155-66. PMC: 1857267. DOI: 10.1172/JCI31422. View

20.

Asano T, McLeod R . Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev. 2004; (2):CD004079. PMC: 8788062. DOI: 10.1002/14651858.CD004079.pub2. View